Loren D. Walensky
Professor
Pediatric Hematologic MalignanciesÂ
Dana-Farber Cancer Institute
United States of America
Biography
Dr. Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in Pediatrics and then completed a fellowship in pediatric hematology-oncology at DFCI and Children's Hospital Boston in 2003. He is board-certified in general pediatrics and pediatric hematology-oncology. He joined DFCI in 2003 and was named medical director of the new Program in Cancer Chemical Biology in 2005.
Research Interest
Hematologic malignancies
Publications
-
Huhn AJ, Guerra RM, Harvey EP, Bird GH, Walensky LD. Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. Cell Chem Biol 2016; 23:1123-34.Â
-
Bird GH, Mazzola E, Opoku-Nsiah K, Lammert MA, Godes M, Neuberg DS, Walensky LD. Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nat Chem Biol 2016
-
Edwards AL, Meijer DH, Guerra RM, Molenaar RJ, Alberta JA, Bernal F, Bird GH, Stiles CD, Walensky LD. Challenges in Targeting a Basic Helix-Loop-Helix Transcription Factor with Hydrocarbon-Stapled Peptides. ACS Chem Biol 2016.
